Can You Still Advertise Compounded GLP-1s With B12 or Niacinamide Added?

What this means for you

• FDA's letter treats GLP-1s with niacinamide or B12 added as possible essential copies of the approved drugs when the difference is not a genuine, individual clinical decision.
• The legal test is a change made for an identified individual patient that produces a significant difference for that patient, as determined by the prescriber. An ad can't make that determination for anyone.
• Ads and landing pages that sell the blend by name, as a standard product with one price, describe the opposite of an individual determination.
• Claims that the additive reduces side effects or improves results are health claims that need competent and reliable scientific evidence.
• Advertise the program and the clinician's decision, and let the prescription settle the formulation.

MedScale Health, a paid ads agency for US telehealth brands and clinics on Meta, Google, Microsoft and TikTok, is regularly asked whether a compounded GLP-1 with B12 or niacinamide added can still be advertised. This page covers what FDA's letter to Empower Pharmacy says, what it means for ad copy, and what to run instead. This page is marketing guidance, not medical or legal advice. Platform policies and FDA positions change, so check the sources listed at the end before acting on a specific rule.

What FDA's letter says

As of October 2026, the clearest statement of FDA's view is warning letter 738238, dated September 18, 2026, to Empower Clinic Services, LLC dba Empower Pharmacy, after an inspection in November 2025. It says investigators collected evidence indicating the pharmacy compounded essential copies of commercially available drugs regularly and in inordinate amounts, naming tirzepatide/niacinamide and semaglutide/cyanocobalamin (vitamin B12) products "which appear to be essentially copies of FDA-approved semaglutide and tirzepatide products."

The letter adds that "the volume of products you are producing suggests that differences between products you are compounding and the FDA-approved products are pretextual." The evidence it lists includes orders that lacked any prescriber determination of significant difference, and orders with purported determinations of "significant difference" that "appear to be repeated verbatim across many records, suggesting that they may be pre-generated for selection by the prescriber, rather than written by the prescriber for an identified individual patient." FDA also says that third-party technology platforms giving prescribers pre-selected menu options for a statement of significant difference call the individualized nature of those determinations into question.

The letter also cites insanitary conditions and manufacturing violations, and asks the pharmacy to respond within 15 working days; it "notifies you of our concerns and provides you an opportunity to address them." This page describes only what the letter says.

The rule the letter applies

As the letter summarizes it, section 503A of the FD&C Act exempts pharmacy-compounded drugs from FDA approval only under conditions, and one is that a pharmacy must not compound regularly or in inordinate amounts drugs that are essentially copies of a commercially available drug. A compounded drug is not essentially a copy if "there is a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner."

Three parts of that sentence matter for marketing: an identified individual patient, a significant difference for that patient, and a determination by the prescriber. Adding B12 or niacinamide is a change. Whether it produces a significant difference is a clinical judgment about one person, and the letter's point is that the same judgment repeated word for word across many records does not look like one.